These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35659487)

  • 41. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
    de Boer PT; Kelso JK; Halder N; Nguyen TP; Moyes J; Cohen C; Barr IG; Postma MJ; Milne GJ
    Vaccine; 2018 Feb; 36(7):997-1007. PubMed ID: 29373192
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
    Dolk C; Eichner M; Welte R; Anastassopoulou A; Van Bellinghen LA; Poulsen Nautrup B; Van Vlaenderen I; Schmidt-Ott R; Schwehm M; Postma M
    Pharmacoeconomics; 2016 Dec; 34(12):1299-1308. PubMed ID: 27647004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A systematic review of the health economic consequences of quadrivalent influenza vaccination.
    de Boer PT; van Maanen BM; Damm O; Ultsch B; Dolk FCK; Crépey P; Pitman R; Wilschut JC; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):249-265. PubMed ID: 28613092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation.
    Omer I; Rosenberg A; Sefty H; Pando R; Mandelboim M; Mendelson E; Keinan-Boker L; Glatman-Freedman A;
    Vaccine; 2022 Feb; 40(6):880-885. PubMed ID: 35016804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults.
    Vanderven HA; Barr I; Reynaldi A; Wheatley AK; Wines BD; Davenport MP; Hogarth PM; Kent SJ
    Vaccine; 2020 Feb; 38(10):2368-2377. PubMed ID: 32035709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
    Vesikari T; Nauta J; Lapini G; Montomoli E; van de Witte S
    Int J Infect Dis; 2020 Mar; 92():29-37. PubMed ID: 31838217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
    Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
    BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
    Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
    PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.
    Domnich A; Arata L; Amicizia D; Puig-Barberà J; Gasparini R; Panatto D
    Vaccine; 2017 Jan; 35(4):513-520. PubMed ID: 28024956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
    García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
    Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea.
    Choi EJ; Park JH; Chun BC
    Vaccine; 2020 Jul; 38(32):5002-5008. PubMed ID: 32532543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine.
    Jain VK; Chandrasekaran V; Wang L; Li P; Liu A; Innis BL
    BMC Infect Dis; 2014 Mar; 14():133. PubMed ID: 24606983
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18-64 years: A systematic review and Meta-analysis].
    Meng ZY; Zhang JY; Zhang ZG; Luo D; Yang XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec; 39(12):1636-1641. PubMed ID: 30572392
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
    Huang C; Fu X; Zhou Y; Mi F; Tian G; Liu X; Wu J; Ding C; Yan D; Li L; Yang S
    Vaccine; 2020 Feb; 38(6):1332-1344. PubMed ID: 31948819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Redondo E; Drago G; López-Belmonte JL; Guillén JM; Bricout H; Alvarez FP; Callejo D; Gil de Miguel Á
    Vaccine; 2021 Aug; 39(36):5138-5145. PubMed ID: 34344553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.